China Foreign Brand Boycott To Spill To Health Sector?
Cotton Row, China Risk and Ways Forward
Executive Summary
Amid a rising tide of sentiment against foreign consumer brands in China, observers say the impact could be far-reaching. But other factors may be more important than public opinion, and innovation will remain a key to success for health sector players.
You may also be interested in...
China COVID-19 Vaccines Efficacy Inadequate? Hot Debate, Variant Worries Swirl
China's regulators and spin doctors rush to remedy a comment from the nation’s top infectious disease official about the “not high” protection rate for its COVID-19 vaccines, amid debate over speedy development using mature technologies and doubts over protection in seniors. A slow roll-out is already presenting challenges to meeting an official 40% target.
Pharma Not Immune From Coming Antitrust Wave In China
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. While the pharma sector remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.
Alibaba's Historic $2.8bn Fine Signals Coming Antitrust Wave In China
China's historic antitrust fine against Alibaba indicates regulatory attention to anticompetitive practices is mounting. Past cases show the pharma sector is not immune and while it remains segmented, investigators appear to be taking a generally more sophisticated approach to transgressions.